Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 9, 2019
Mission Possible: Advances in MYC Therapeutic Targeting in CancerBrittany L Allen-Petersen, Rosalie C Sears
NAR Cancer|February 4, 2022
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happenSamantha L Tinsley, Brittany L Allen-Petersen
PNAS Nexus|January 30, 2023
Sustained degradation of hyaluronic acid using an in situ forming implantKelsey Hopkins, Kevin Buno, Natalie Romick, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 14, 2014
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancerMahnaz Janghorban, Amy S Farrell, Brittany L Allen-Petersen, et al.
Pharmaceutics|April 23, 2022
Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic CancerVidhi M Shah, Craig Dorrell, Adel Al-Fatease, et al.
Heliyon|March 11, 2024
Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cellsDmytro Grygoryev, Taelor Ekstrom, Elise Manalo, et al.
The Journal of Biological Chemistry|December 12, 2019
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancersCaroline C Farrington, Eric Yuan, Sahar Mazhar, et al.
STAR Protocols|March 6, 2025
Protocol to purify and culture human pancreatic cancer cells from patient-derived xenograftsJulien Tessier, Dmytro Grygoryev, Marilynn Chow-Castro, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinomaGarima Baral, Claire M Pfeffer, Sara N Filippelli, et al.
Cancer Research|November 4, 2018
Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal AdenocarcinomaBrittany L Allen-Petersen, Tyler Risom, Zipei Feng, et al.
Pageof 3